Erratum: Should people at low risk of cardiovascular disease take a statin? (BMJ (Online) (2013) 347 (f6123) DOI:10.1136/bmj.f6123);Should people at low risk of cardiovascular disease take a statin?

BMJ (Online)

Volumn 347, Issue 7930, 2013, Pages

  Abramson, John D ^a   Rosenberg, Harriet G ^b   Jewell, Nicholas ^c   Wright, James M ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b YORK UNIVERSITY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN;

ACUTE KIDNEY FAILURE; AMNESIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CATARACT; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; ENERGY; FATIGUE; HEPATITIS; HUMAN; LIVER DYSFUNCTION; LOW RISK POPULATION; MENTAL DISEASE; MUSCLE DISEASE; MYOPATHY; NEUROPATHY; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT;

EID: 84886608030     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g3329     Document Type: Erratum

References (28)

1. Taylor F, Huffman MD, Macedo AF, Moore T H M, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816.
2. Taylor F, Ward K, Moore T H M, Burke M, Davey Smith G, Casas JP, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011;1:CD004816.
3. NICE. Statins for the prevention of cardiovascular events. Technology appraisal 94. NICE, 2008.
4. Mosca L, Benjamin, EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation 2011;123:1243-62.
5. Ferreira-González I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007;334:786.
6. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1437.
7. Ebrahim S, Casas JP. Statins for all by the age of 50 years? Lancet, 2012;380:545-7.
8. CTT (Cholesterol Treatment Trialists' Collaboration). www.ctsu.ox.ac.uk/research/metatrials/ctt/ctt-website.
9. Nissen SE, Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach? J Am Coll Cardiol 2009;54:2363-5.
10. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90.
11. Wood L, Egger M, Gluud LL, Jüni P, Altman DG, Gluud C, et al. Empirical evidence of bias in treatment efect estimates in controlled trials with diferent interventions and outcomes: meta-epidemiological study, BMJ 2008;336:601.
12. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar. P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013;158:526-34.
13. Buettner CA, Davis RB, Leveille SG, Mittleman MA, Mukamal KJ. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med 2008;23:1182-6.
14. Mansi I, Frei CR, Pugh MJ, Makris U, Mortensen EM. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med 2013;73:1-10.
15. Mikus CR, Boyle LJ, Borengasser SJ, Oberlin DJ, Naples SP, Fletcher J, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol 2013;62:709-14.
16. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia. Circulation 2010;121:1069-77.
17. Culver AL, Ockene IS, Balasubramanian R, Olenzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172:144-52.
18. Hippisley-Cox H, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database, BMJ 2010;340:c2197.
19. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Dis 2008;8:373-418.
20. Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 2012;172:1180-2.
21. Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe implications for the use of lipid-lowering agents. Drug Safety 2007;30:195-201. (Pubitemid 46425633)
22. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012;12: MR000033.
23. Mansi I, Mortensen E. The controversy of a wider statin utilization: why? Expert Opin Drug Saf 2013:12:327-37.
24. Donnelly LA, Doney AS, Morris AD, Palmer CN, Donnan PT. Long-term adherence to statin treatment in diabetes. Diabet Med 2008;25:850-5.
25. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep 2013;15:291-8.
26. Pharmacy Checker. Zocor pricing and ordering comparisons. www.pharmacychecker.com/compare-drug-prices-online-pharmacies/zocor-20+mg/19487/ 31766/.
27. Naci H, Ionnidis J P A. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ 2013;347:f5577.
28. World Health Organization. Global status report on noncommunicable diseases. 2010. http://whqlibdoc.who.int/publications/2011/9789240686458-eng. pdf.